

In the Specification

Please amend the paragraph beginning on line 4 of page 1, as follows:

Cross-Reference to Related Applications

This application is a continuation in part application of U.S. application Serial No.

[] 09/825,129, filed on April 3, 2001, which claims the benefit of the filing date of U.S. application Serial No. 60/194,334 under 35 U.S.C. § 119(e).

Please amend the paragraph beginning on line 6 of page 10, please amend as follows:

A number of naturally occurring proteins and other small molecules can inhibit angiogenesis. This group includes but is not limited to angiostatin, endostatin, and thrombospondin-1 ~~thrombospondin-7~~, as well as interferons (alpha, beta and gamma), platelet factor 4, prolactin 16 Kd fragment, antiangiogenic antithrombin III, cartilage-derived inhibitor (CDI), CD59 complement fragment, fibronectin fragment, gro-beta, heparinases, heparin hexasaccharide fragment, human chorionic gonadotropin (hCG), interferon inducible protein (IP-10), interleukin-12, kringle 5 (plasminogen fragment), 2-methoxyestradiol, placental ribonuclease inhibitor, plasminogen activator inhibitor, proliferin-related protein (PRP), retinoids, tetrahydrocortisol-S, transforming growth factor-beta (TGF-beta), vasculostatin, vasostatin (calreticulin fragment), tissue inhibitor of metalloproteinase-1 (TIMP-1), tissue inhibitor of metalloproteinase-2 (TIMP-2), and tissue inhibitor of metalloproteinase-3 (TIMP-3) (see for example the <http://www.nci.nih.gov/> URL “www.nci.nih.gov/”). According to the National Cancer Institute, about 20 angiogenesis inhibitors are currently being tested in human trials. Most are in early phase I or II clinical (human) studies. Some are in or entering phase III testing. See URL “cancertrials.nci.nih.gov/news/angio/table.html”

<http://cancertrials.nci.nih.gov/news/angio/table.html> for a list of angiogenesis inhibitors in clinical trials. These inhibitors include agents that block matrix breakdown, e.g., marimastat, COL-3, neovastat, and BMS-275291; agents that block angiogenesis activators, e.g., SU5416, SU6668, interferon α, anti-VEGF antibody; agents that directly inhibit endothelial cells, e.g., thalidomide; squalamine ~~squalimine~~, endostatin; agents that inhibit endothelial-specific integrin signaling, e.g., EMD 121974; and others, e.g., CAI, interleukin-12, and IM862. Thus, it is also

envisioned that any of these antiangiogenic moieties may be linked to a targeting moiety of the invention.